juli Co-Founder authors in Scientific American’s Special Report on Mental Health

Have you met our co-founder, Joseph Hayes? He holds an MSc in epidemiology from the London School of Hygiene and Tropical Medicine, and a PhD in psychiatric epidemiology from UCL. When he’s not putting these smarts to work at juli to revolutionize the way people manage their chronic diseases, he is a Wellcome Clinical Fellow at the Division of Psychiatry at UCL, sitting on the World Economic Forum Global Future Council on Mental Health, and serving on the editorial board of the British Journal of Psychiatry and the International Journal of Bipolar Disorders. Not to mention he’s an honorary consultant psychiatrist public health consultant.

And amidst all of these contributions to neuroscience and population health, Joseph recently co-authored an opinion piece in Scientific American on the use of novel drug therapies to tackle treatment-resistant depression. The piece is part of a special report series on The Top 10 Innovations in Mental Health.

Why the focus on this topic? Because depression affects more than 264 million people around the world, and is the psychiatric diagnosis most commonly associated with suicide—and yet drug development for depression has stalled for a number of years. Approximately one third of those suffering from depression are considered treatment-resistant, meaning they don’t respond to two or more antidepressants. Joseph’s piece highlights several new antidepressants that work through completely different mechanisms than traditional treatments— scientific advances that are exciting and hugely promising.

Read the full article here, share it with your community, and join Juli across social networks for more insight into Joseph’s commitment to advancing the fields of mental health and neuroscience.